Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale University · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
pembrolizumab
t-cell lymphoma, relapsed, refractory, cd30 positive, peripheral t-cell lymphoma, cutaneous t-cell lymphoma, pembrolizumab, brentuximab, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 833712
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.